Literature DB >> 26810345

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

Annika Herlemann1, Vera Wenter2, Alexander Kretschmer1, Kolja M Thierfelder3, Peter Bartenstein4, Claudius Faber5, Franz-Josef Gildehaus2, Christian G Stief6, Christian Gratzke6, Wolfgang P Fendler7.   

Abstract

We evaluated the accuracy of 68Ga-prostate-specific membrane antigen-HBED-CC (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) for nodal staging prior to lymph node dissection (LND) in patients with prostate cancer (PCa). Thirty-four patients with histologically proven PCa underwent 68Ga-PSMA-HBED-CC PET/CT prior to radical prostatectomy with primary LND (pLND; n=20) and PET/CT prior to secondary LND (sLND; n=14). Accuracy of PET and CT were analysed separately for staging of the following 71 lymph node (LN) regions: pelvic left (n=30), pelvic right (n=31), presacral (n=3), and para-aortic (n=7). Postoperative histopathology was taken as a reference standard. Thirty-seven of 71 (52%) regions showed LN metastases on histopathology. Sensitivity, specificity, positive predictive value, and negative predictive value for detection of LN metastases were 84%, 82%, 84%, and 82% for PET criteria and 65%, 76%, 75%, and 67% for CT criteria. PET was more accurate for nodal staging compared with CT both at pLND (88% vs 75%) and sLND (77% vs 65%). Overall, 68Ga-PSMA PET/CT provides accurate nodal staging prior to pLND and sLND for PCa. PATIENT
SUMMARY: 68Ga-PSMA positron emission tomography/computed tomography is accurate in detecting tumour spread to lymph nodes before patients undergo surgery for prostate cancer.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lymph node dissection; PET/CT; PSMA; Positron emission tomography; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26810345     DOI: 10.1016/j.eururo.2015.12.051

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  85 in total

Review 1.  Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.

Authors:  Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

2.  [Uncommon manifestation of prostate cancer : Sister Mary Joseph's nodule].

Authors:  T Hansen; M Weckesser; M Schäfers; A Gunnemann
Journal:  Urologe A       Date:  2017-01       Impact factor: 0.639

3.  Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Authors:  Michael A Gorin; Steven P Rowe; Hiten D Patel; Igor Vidal; Margarita Mana-Ay; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Edward M Schaeffer; Trinity J Bivalacqua; Alan W Partin; Kenneth J Pienta; Zsolt Szabo; Angelo M De Marzo; Martin G Pomper; Mohamad E Allaf
Journal:  J Urol       Date:  2017-07-20       Impact factor: 7.450

4.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

5.  [When is surgical treatment indicated in metastatic prostate cancer and what is the scientific rationale?]

Authors:  A Kretschmer; A Herlemann; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 6.  [Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer].

Authors:  A Afshar-Oromieh; I Alberts; C Sachpekidis; A Rominger
Journal:  Urologe A       Date:  2019-12       Impact factor: 0.639

7.  Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.

Authors:  Alexis Lépinoy; Yannick E Silva; Etienne Martin; Aurélie Bertaut; Magali Quivrin; Léone Aubignac; Alexandre Cochet; Gilles Créhange
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236

8.  Intraoperative 68Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study.

Authors:  Christopher Darr; Nina N Harke; Jan Philipp Radtke; Leubet Yirga; Claudia Kesch; Maarten R Grootendorst; Wolfgang P Fendler; Pedro Fragoso Costa; Christoph Rischpler; Christine Praus; Johannes Haubold; Henning Reis; Thomas Hager; Ken Herrmann; Ina Binse; Boris Hadaschik
Journal:  J Nucl Med       Date:  2020-02-14       Impact factor: 10.057

Review 9.  PET imaging for lymph node dissection in prostate cancer.

Authors:  Elena Incerti; Paola Mapelli; Luigi Gianolli; Maria Picchio
Journal:  World J Urol       Date:  2016-10-17       Impact factor: 4.226

Review 10.  PSMA PET and Radionuclide Therapy in Prostate Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.